Obinutuzumab Pretreatment as a Novel Approach to Mitigate Formation of Anti-Drug Antibodies Against Cergutuzumab Amunaleukin in Patients with Solid Tumors.
Solange PetersEric AngevinTeresa Alonso GordoaKristoffer Staal RohrbergIgnacio Melero BermejoBegona MelladoJose-Luis Perez-GraciaJosep TaberneroCeline AdessiChristophe BoetschCarl WatsonJoseph Dal PortoDavid DejardinChristopher Del NagroValeria NicoliniStefan EversChristiane NeumannBarbara LeutgebPavel PisaEva RossmannJosé SaroPablo UmañaJehad CharoVolker TeichgräberNeeltje SteeghsPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2024)
These preliminary findings suggest that obinutuzumab pretreatment before CEA-IL2v administration in patients with CEA+ solid tumors may be a feasible and potent ADA mitigation strategy, with an acceptable safety profile, supporting broader investigation of obinutuzumab pretreatment for ADA mitigation in other settings.